Apatinib preferentially inhibits PC9 gefitinib-resistant cancer cells by inducing cell cycle arrest and inhibiting VEGFR signaling pathway

BACKGROUND: Lung cancer is one of the most common and deadly tumors around the world. Targeted therapy for patients with certain mutations, especially by use of tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR), has provided significant benefit to patients. However,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell Int
Main Authors: Song, Yong-An, Ma, Ting, Zhang, Xue-Yan, Cheng, Xiang-Song, Olajuyin, Ayobami-Matthew, Sun, Zhi-Fu, Zhang, Xiao-Ju
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2019
Assuntos:
Primary Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6498592/
https://ncbi.nlm.nih.gov/pubmed/31073278
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-019-0836-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados